About Avrobio
Avrobio is a company based in Cambridge (United States) founded in 2016.. Avrobio has raised $85.5 million across 3 funding rounds from investors including Blackstone, Citadel and Atlas Venture. The company has 114 employees as of December 31, 2022. Avrobio operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 114 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
$-105.89 M11as on Dec 31, 2022
-
EBITDA
$-105.43 M11as on Dec 31, 2022
-
Total Equity Funding
$85.5 M (USD)
in 3 rounds
-
Latest Funding Round
$60.5 M (USD), Series B
Feb 01, 2018
-
Investors
Blackstone
& 8 more
-
Employee Count
114
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Avrobio
Avrobio has successfully raised a total of $85.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $60.5 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $60.5M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2018 | Amount | Series B - Avrobio | Valuation | Citadel | |
| Aug, 2016 | Amount | Series A - Avrobio | Valuation | Atlas Venture , Blackstone |
|
| Feb, 2016 | Amount | Seed - Avrobio | Valuation | Atlas Venture |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Avrobio
Avrobio has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, Citadel and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Brace Pharma Capital is focused on investing in innovative therapies.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avrobio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Avrobio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avrobio Comparisons
Competitors of Avrobio
Avrobio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Avrobio
Frequently Asked Questions about Avrobio
When was Avrobio founded?
Avrobio was founded in 2016.
Where is Avrobio located?
Avrobio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Avrobio a funded company?
Avrobio is a funded company, having raised a total of $85.5M across 3 funding rounds to date.
How many employees does Avrobio have?
As of Dec 31, 2022, the latest employee count at Avrobio is 114.
What does Avrobio do?
Avrobio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Focus is placed on gene therapies for genetic diseases, particularly lysosomal disorders. A proprietary Plato platform is utilized to create lentiviral-based treatments. The pipeline encompasses AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 for Hunter syndrome. Operations center on research and development in this specialized field.
Who are the top competitors of Avrobio?
Avrobio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Avrobio's investors?
Avrobio has 9 investors. Key investors include Blackstone, Citadel, Atlas Venture, Brace Pharma Capital, and Eventide Mutual Funds.